Related Experiment Videos
Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function
Siobhan Robinson1, Pierre Freeman, Cynthia Moore
1Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, OR 97201, USA.
Experimental Neurology
|April 2, 2003
Summary
Bilateral dopamine loss in mice affects striatal glutamate function differently based on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) dosing. Acute MPTP treatment reduced glutamate and GluR-2/3 levels, unlike subchronic treatment.
Area of Science:
- Neuroscience
- Neuropharmacology
- Neurochemistry
Background:
- Striatal dopamine depletion is linked to altered glutamate function.
- Understanding these changes is crucial for neurodegenerative disease research.
Purpose of the Study:
- To investigate the impact of bilateral striatal dopamine loss on striatal glutamate function.
- To compare the effects of acute versus subchronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration.
Main Methods:
- C57/B6J mice received acute or subchronic MPTP or saline injections.
- Tyrosine hydroxylase (TH) immunolabeling assessed dopamine loss.
- In vivo microdialysis measured extracellular glutamate.
- Immuno-gold electron microscopy evaluated glutamate and GluR-2/3 immunolabeling.
Main Results:
- Both MPTP regimens caused significant striatal TH loss, with acute treatment showing a greater reduction.
- Subchronic MPTP decreased basal striatal glutamate, while acute MPTP increased it.
- Acute MPTP uniquely reduced glutamate and GluR-2/3 immunolabeling in nerve terminals.
Conclusions:
- Dosing interval of MPTP significantly influences striatal glutamate function and TH loss.
- Acute MPTP administration leads to distinct alterations in glutamatergic neurotransmission compared to subchronic treatment.